{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:52:01Z","timestamp":1791528721884,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["NTUH 113-A170"],"award-info":[{"award-number":["NTUH 113-A170"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jfma.2025.06.024","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T18:22:30Z","timestamp":1750270950000},"page":"1385-1391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of dosimetry models to predict outcome for radioembolization in patients with intermediate to advanced hepatocellular carcinoma"],"prefix":"10.1016","volume":"125","author":[{"given":"Hui-Chi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Hsuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Uen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7498-4183","authenticated-orcid":false,"given":"Chih-Horng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.jfma.2025.06.024_bib1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jfma.2025.06.024_bib2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jfma.2025.06.024_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jfma.2025.06.024_bib4","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jfma.2025.06.024_bib5","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.annonc.2019.12.001","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO","volume":"31","author":"Chen","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jfma.2025.06.024_bib6","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jfma.2020.10.031","article-title":"Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan","volume":"120","author":"Shao","year":"2021","journal-title":"J Formos Med Assoc"},{"issue":"6","key":"10.1016\/j.jfma.2025.06.024_bib7","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"issue":"19","key":"10.1016\/j.jfma.2025.06.024_bib8","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jfma.2025.06.024_bib9","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jfma.2025.06.024_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2025.06.024_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3389\/fonc.2014.00210","article-title":"Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective","volume":"4","author":"Cremonesi","year":"2014","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jfma.2025.06.024_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijrobp.2006.11.060","article-title":"Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium","volume":"68","author":"Kennedy","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.jfma.2025.06.024_bib13","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.ijrobp.2008.10.005","article-title":"Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors","volume":"74","author":"Kennedy","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.jfma.2025.06.024_bib14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/BF01084369","article-title":"Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours","volume":"23","author":"Ho","year":"1996","journal-title":"Eur J Nucl Med"},{"issue":"2","key":"10.1016\/j.jfma.2025.06.024_bib15","article-title":"Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: results from the prospective CIRT study","volume":"5","author":"Kolligs","year":"2023","journal-title":"JHEP Rep."},{"issue":"7","key":"10.1016\/j.jfma.2025.06.024_bib16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12149-011-0499-6","article-title":"Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review","volume":"25","author":"Kao","year":"2011","journal-title":"Ann Nucl Med"},{"issue":"2","key":"10.1016\/j.jfma.2025.06.024_bib17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ijrobp.2009.06.069","article-title":"Computer modeling of yttrium-90-microsphere transport in the hepatic arterial tree to improve clinical outcomes","volume":"76","author":"Kennedy","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jfma.2025.06.024_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amsu.2020.04.001","article-title":"Total tumor volume as a prognostic value for survival following liver resection in patients with hepatocellular carcinoma. Retrospective cohort study","volume":"54","author":"Zakaria","year":"2020","journal-title":"Ann Med Surg (Lond)"},{"issue":"Suppl 2","key":"10.1016\/j.jfma.2025.06.024_bib19","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1002\/lt.22365","article-title":"Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience","volume":"17","author":"Mazzaferro","year":"2011","journal-title":"Liver Transplant"},{"issue":"6","key":"10.1016\/j.jfma.2025.06.024_bib20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1159\/000517393","article-title":"Redefining tumor burden in patients with intermediate-stage hepatocellular carcinoma: the seven-eleven criteria","volume":"10","author":"Hung","year":"2021","journal-title":"Liver Cancer"},{"issue":"8","key":"10.1016\/j.jfma.2025.06.024_bib21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4254\/wjh.v12.i8.525","article-title":"\"Six-and-twelve\" score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort","volume":"12","author":"Adhoute","year":"2020","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1016\/j.jfma.2025.06.024_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"11","key":"10.1016\/j.jfma.2025.06.024_bib23","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jvir.2015.07.021","article-title":"Intrahepatic activity distribution in radioembolization with yttrium-90-labeled resin microspheres using the body surface area method--A less than perfect model","volume":"26","author":"Grosser","year":"2015","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jfma.2025.06.024_bib24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejmp.2019.09.236","article-title":"A guide to (90)Y radioembolization and its dosimetry","volume":"68","author":"Kim","year":"2019","journal-title":"Phys Med"},{"issue":"11","key":"10.1016\/j.jfma.2025.06.024_bib25","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1007\/s00259-019-04427-z","article-title":"Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study","volume":"46","author":"Levillain","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.jfma.2025.06.024_bib26","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","article-title":"International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres","volume":"48","author":"Levillain","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"4","key":"10.1016\/j.jfma.2025.06.024_bib27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1055\/s-0041-1732323","article-title":"Standard radiation dosimetry models: what interventional radiologists need to know","volume":"38","author":"Webster","year":"2021","journal-title":"Semin Interv Radiol"},{"issue":"19","key":"10.1016\/j.jfma.2025.06.024_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194908","article-title":"Role of resin microsphere Y90 dosimetry in predicting objective tumor response, survival and treatment related toxicity in surgically unresectable colorectal liver metastasis: a retrospective single institution study","volume":"13","author":"Sankhla","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.jfma.2025.06.024_bib29","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.2967\/jnumed.115.166942","article-title":"Insights into the dose\u2013response relationship of radioembolization with resin 90Y-microspheres: a prospective cohort study in patients with colorectal cancer liver metastases","volume":"57","author":"Van Den Hoven","year":"2016","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.jfma.2025.06.024_bib30","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1148\/radiol.2020191606","article-title":"Relationship of tumor radiation\u2013absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH study","volume":"296","author":"Hermann","year":"2020","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.jfma.2025.06.024_bib31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","article-title":"Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma","volume":"68","author":"Chew","year":"2019","journal-title":"Gut"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625002980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625002980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:45:41Z","timestamp":1791528341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625002980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0929664625002980"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.06.024","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of dosimetry models to predict outcome for radioembolization in patients with intermediate to advanced hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}